Table 3.
Piecewise analyses for primary and secondary outcome variables over time
| Time Period | Abstinencea B (se) |
t | % Days Use B (se) |
t | MPSb B (se) |
t | Self-Efficacyc B (se) |
t | Copingd B (se) |
t |
|---|---|---|---|---|---|---|---|---|---|---|
| Intake to ETX: | ||||||||||
| BRIEF | 0.66(1.07) | 0.6 | −0.48(0.09) | −5.5*** | −4.89(1.79) | −2.7** | 0.25(0.39) | 0.6 | 0.24(0.18) | 1.3 |
| vs. THERAPIST | 2.45(1.10) | 2.2* | −0.16(0.11) | −1.6 | −1.26(2.15) | −0.6 | 0.97(0.46) | 2.1* | 0.31(0.22) | 1.4 |
| vs. COMPUTER | 2.28(1.12) | 2.0* | −0.14(0.10) | −1.3 | −2.44(2.23) | −1.1 | 1.04(0.48) | 2.2* | 0.39(0.23) | 1.7 |
| THERAPIST vs. COMPUTER | 0.17 (0.75) | 0.2 | −0.03 (0.09) | −0.3 | 1.18 (1.85) | 0.6 | −0.06 (0.40) | −0.1 | −0.08 (0.19) | −0.5 |
| ETX to 3mo: | ||||||||||
| BRIEF | −1.02(1.40) | −0.7 | −0.09(0.10) | −0.9 | 3.68(2.16) | 1.7 | 0.61(0.49) | 1.3 | 0.12(0.22) | 0.6 |
| vs. THERAPIST | −0.34(1.5) | −0.2 | 0.09(0.12) | 0.7 | −6.23(2.66) | −2.4* | −1.21(0.58) | −2.1* | −0.39(0.27) | −1.4 |
| vs. COMPUTER | 0.51(1.54) | 0.3 | 0.16(0.12) | 1.3 | −2.47(2.66) | −0.9 | −1.00(0.58) | −1.7 | −0.40(0.27) | −1.5 |
| THERAPIST vs. COMPUTER | −0.85 (0.90) | −0.9 | −0.07(0.10) | −0.7 | −3.77 (2.19) | −1.7 | −0.23 (0.47) | −0.5 | 0.010 (0.22) | 0.1 |
| 3mo to 9mo: | ||||||||||
| BRIEF | −0.00(0.83) | −0.0 | 0.05(0.06) | 0.8 | −2.73(1.35) | 2.0* | −0.36(0.30) | −1.2 | −0.17(0.14) | −1.2 |
| vs. THERAPIST | −0.47(0.92) | −0.5 | 0.09(0.07) | 1.3 | 3.63(1.64) | 2.2* | 0.44(0.36) | 1.2 | 0.13(0.17) | 0.8 |
| vs. COMPUTER | −0.48(0.90) | −0.5 | −0.05(0.7) | 0.7 | 1.93(1.60) | 1.2 | 0.36(0.36) | 1.0 | −0.08(0.16) | −0.5 |
| THERAPIST vs. COMPUTER | 0.006 (0.54) | 0.01 | 0.14 (0.05) | 2.5* | 1.69 (1.26) | 1.4 | 0.072 (0.28) | 0.26 | 0.21 (0.13) | 1.6 |
***
p<.001
**
p<.01
*
p<.05
a
% of participants with cannabis−negative urine test at each assessment
b
Score on the Marijuana Problem Scale
c
Score on the Self-Efficacy Scale
d
Score on the Total Coping Strategy Scale